Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LE-MPP
- Development stage
- Unknown
- Lead developer
- Kala Bio
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
LE-MPP is an ophthalmic formulation of the topical corticosteroid loteprednol etabonate engineered with Kala Pharmaceuticals’ mucus-penetrating particle (MPP) nanotechnology to enhance drug delivery to ocular tissues.[4][6] By coating drug-loaded nanoparticles to rapidly traverse the tear film mucus, LE-MPP achieves higher and more sustained loteprednol etabonate concentrations in the cornea, conjunctiva, aqueous humor and retina compared with conventional suspensions or gels, supporting development for anterior and posterior segment inflammatory eye diseases including post–cataract surgery inflammation and pain, retinal vein occlusion, diabetic macular edema, and meibomian gland disease.[2][4][6]
- Other names
- loteprednol etabonate MPPLE MPP
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on LE-MPP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LE-MPP.